JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Lista de Ações・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Fechado

SetorSaúde

21.95 -2.4

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

21.69

Máximo

Indicadores-chave
By Trading Economics
Rendimento	202M 274M
Vendas	5.4M 284M
P/E Médio do Setor	9.696 67.147
Margem de lucro	96.33
Funcionários	796
EBITDA	-21M 26M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+40.49% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-366M 3.8B
Abertura anterior	24.35
Fecho anterior	21.95

Sentimento de Notícias

By Acuity

28%

72%

79 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

14.845 / N/A Suporte e Resistência

ACADIA Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

1 de mai. de 2026, 21:36 UTC

Aquisições, Fusões, Aquisições de Empresas

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1 de mai. de 2026, 20:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1 de mai. de 2026, 18:37 UTC

Grandes Movimentos do Mercado

Senseonic Shares Slide on Underwritten Offering Price

1 de mai. de 2026, 16:46 UTC

Grandes Movimentos do Mercado

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

1 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

1 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

1 de mai. de 2026, 20:42 UTC

Ganhos

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1 de mai. de 2026, 19:33 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 de mai. de 2026, 19:33 UTC

Conversa de Mercado

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1 de mai. de 2026, 19:18 UTC

Conversa de Mercado

Notícias Principais

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1 de mai. de 2026, 19:13 UTC

Conversa de Mercado

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1 de mai. de 2026, 18:36 UTC

Ganhos

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1 de mai. de 2026, 18:35 UTC

Ganhos

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 de mai. de 2026, 18:28 UTC

Ganhos

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1 de mai. de 2026, 18:27 UTC

Conversa de Mercado

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1 de mai. de 2026, 18:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Barclays Completes Acquisition of Best Egg

1 de mai. de 2026, 18:04 UTC

Ganhos

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1 de mai. de 2026, 17:43 UTC

Conversa de Mercado

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1 de mai. de 2026, 17:37 UTC

Conversa de Mercado

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1 de mai. de 2026, 17:30 UTC

Conversa de Mercado

Ganhos

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1 de mai. de 2026, 17:28 UTC

Conversa de Mercado

Ganhos

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1 de mai. de 2026, 17:21 UTC

Conversa de Mercado

Ganhos

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1 de mai. de 2026, 17:19 UTC

Conversa de Mercado

Notícias Principais

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1 de mai. de 2026, 16:38 UTC

Conversa de Mercado

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1 de mai. de 2026, 16:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

1 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

1 de mai. de 2026, 16:15 UTC

Ganhos

This AI Stock Is Up 78% This Year. Why It Still Looks Like a Buy. -- Barrons.com

1 de mai. de 2026, 16:11 UTC

Conversa de Mercado

Bank of Canada Committed a 'Messaging Blunder' -- Market Talk

1 de mai. de 2026, 16:04 UTC

Ganhos

Exxon Stock Slips. CEO Warns 'Full Impact' of War is Coming. -- Barrons.com

Comparação entre Pares

Variação de preço

ACADIA Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

40.49% parte superior

Previsão para 12 meses

Média 31.54 USD 40.49%

Máximo 40 USD

Mínimo 23 USD

Com base em 15 analistas de Wall Street que oferecem metas de preço de 12 meses para ACADIA Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

15 ratings

Comprar

Manter

Vender

Com base em 15 analistas que deram avaliações de ações para ACADIA Pharmaceuticals Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

14.845 / N/ASuporte e Resistência

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentimento

By Acuity

79 / 347 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.